Lai Li Investment Company

Eli Lilly (China) Investment Co., Ltd. serves as the strategic investment and management headquarters for Eli Lilly and Company's operations in China. Based in Shanghai, the company oversees the research, development, manufacturing, and commercialization of a broad pharmaceutical portfolio focusing on metabolic disorders, oncology, immunology, and neuroscience. It is a dominant player in the Chinese healthcare market, particularly recognized for its leadership in diabetes care and its recent breakthroughs in obesity and Alzheimer's disease treatments. The entity also facilitates strategic partnerships with local biotechnology firms to expand Lilly's innovative pipeline and clinical footprint within the region. Through its integrated operations, the company aims to deliver high-quality medical solutions tailored to the specific needs of the Chinese patient population.